@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix RNA: . @prefix rgd: . @prefix geneProductOf: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: rgd:3632; a RNA: . sub:_2 occursIn: obo:UBERON_0000007, species:10116; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject schem:Calcium; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:Calcium) -> r(RGD:Scn2a1)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "20131211" . sub:_3 prov:value "These conditions were then used to assess the transcript levels of Na+ channels after chronic exposure (72 h) of GH3 cells to the L-type Ca2+ channel blocker nimodipine (1 microM) or the L-type channel agonist Bay K 8644 (0.5 microM). Nimodipine treatment caused a moderate reduction (approximately 30%) of the mRNA for Nav1.2 and a marked reduction (approximately 70%) of the mRNA for Nav1.3, whereas treatment with Bay K 8644 produced 90-130% increases in these same mRNAs."; prov:wasQuotedFrom pubmed:12941467 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12941467; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:32:07.638+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }